{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Search Solution\n",
    "https://docs.microsoft.com/en-us/azure/search/search-get-started-python\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Creating an index\n",
    "\n",
    "In an index we need to include a name, a fields collection and a key.\n",
    "\n",
    "The *fields collection* defines the structure of a logical search document. It is used both when loading data and when returning results. \n",
    "\n",
    "Each field has a: name, type and attribute. <- determine how the field is used\n",
    "\n",
    "Within an index, one field **must** be of type `Edm.String` and it will be the *key* for document identity. \n",
    "\n",
    "Attributes -> https://docs.microsoft.com/en-us/azure/search/search-what-is-an-index"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "CorsOptions - https://docs.microsoft.com/en-us/dotnet/api/microsoft.azure.search.models.corsoptions?view=azure-dotnet"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Python Classes -> https://docs.microsoft.com/en-us/python/api/azure-search-documents/azure.search.documents.indexes.searchindexclient?view=azure-python"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Load documents\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "REST API calls \n",
    "\n",
    "Azure Cognitive Search - https://docs.microsoft.com/en-us/rest/api/searchservice/search-documents"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Demo Cognitive Search - Thesis\n",
    "\n",
    "Blob to Cognitive Search -> https://docs.microsoft.com/en-us/azure/search/cognitive-search-tutorial-blob-python"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import requests\n",
    "import os\n",
    "import time\n",
    "from pprint import pprint # pretty printer\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "# Define the names for the data source, skillset, index and indexer\n",
    "datasource_name = \"cogsrch-py-datasource\"\n",
    "skillset_name = \"cogsrch-py-skillset\"\n",
    "index_name = \"cogsrch-py-index\"\n",
    "indexer_name = \"cogsrch-py-indexer\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "load_dotenv()\n",
    "\n",
    "endpoint = os.getenv('SEARCH_ENDPOINT')\n",
    "admin_key = os.getenv('SEARCH_ADMIN_API_KEY')\n",
    "\n",
    "headers = {\n",
    "    'Content-Type':'application/json',\n",
    "    'api-key': admin_key\n",
    "}\n",
    "\n",
    "params = {\n",
    "    'api-version':'2020-06-30'\n",
    "}\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 0. Clear previous existing resources\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "204\n",
      "404\n",
      "404\n",
      "404\n"
     ]
    }
   ],
   "source": [
    "# delete the skillset\n",
    "# status code 204 on success\n",
    "\n",
    "r = requests.delete(endpoint + \"/datasources/\" + datasource_name,\n",
    "                    headers=headers, params=params)\n",
    "print(r.status_code)\n",
    "\n",
    "r = requests.delete(endpoint + \"/skillsets/\" + skillset_name,\n",
    "                    headers=headers, params=params)\n",
    "print(r.status_code)\n",
    "\n",
    "r = requests.delete(endpoint + \"/indexes/\" + index_name,\n",
    "                    headers=headers, params=params)\n",
    "print(r.status_code)\n",
    "\n",
    "r = requests.delete(endpoint + \"/indexers/\" + indexer_name,\n",
    "                    headers=headers, params=params)\n",
    "print(r.status_code)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Create the pipeline\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 1. Create a data source\n",
    "\n",
    "A *data source object* provides the connection string to the Blob container containing the sample data files. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "201\n"
     ]
    }
   ],
   "source": [
    "datasource_connection_string = os.getenv('STORAGE_CONNECTION_STRING')\n",
    "blob_container_name = os.getenv('CONTAINER_NAME')\n",
    "\n",
    "datasource_payload = {\n",
    "    \"name\": datasource_name,\n",
    "    \"description\": \"Article examples\",\n",
    "    \"type\" : \"azureblob\",\n",
    "    \"credentials\": {\n",
    "        \"connectionString\": datasource_connection_string\n",
    "    },\n",
    "    \"container\": {\n",
    "        \"name\": blob_container_name\n",
    "    }    \n",
    "}\n",
    "\n",
    "r = requests.put(endpoint + \"/datasources/\" + datasource_name, \n",
    "                data=json.dumps(datasource_payload), headers=headers, params=params)\n",
    "\n",
    "print(r.status_code)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 2. Create a skillset\n",
    "\n",
    "Set of enrichments that will be applied to the data\n",
    "\n",
    "Create a skillset -> https://docs.microsoft.com/en-us/azure/search/cognitive-search-defining-skillset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "201\n"
     ]
    }
   ],
   "source": [
    "language_detection_skill = {\n",
    "            \"@odata.type\": \"#Microsoft.Skills.Text.LanguageDetectionSkill\",\n",
    "            \"inputs\": [\n",
    "                {\n",
    "                    \"name\": \"text\", \n",
    "                    \"source\": \"/document/content\"\n",
    "                }\n",
    "            ],\n",
    "            \"outputs\": [\n",
    "                {\n",
    "                    \"name\": \"languageCode\",\n",
    "                    \"targetName\": \"languageCode\"\n",
    "                }\n",
    "            ]\n",
    "        } \n",
    "\n",
    "text_split_skill = {\n",
    "            \"@odata.type\": \"#Microsoft.Skills.Text.SplitSkill\",\n",
    "            \"textSplitMode\": \"pages\",\n",
    "            \"maximumPageLength\": 4000,\n",
    "            \"inputs\": [\n",
    "                {\n",
    "                    \"name\": \"text\",\n",
    "                    \"source\": \"/document/content\"\n",
    "                },\n",
    "                {\n",
    "                    \"name\": \"languageCode\",\n",
    "                    \"source\": \"/document/languageCode\"\n",
    "                }\n",
    "            ],\n",
    "            \"outputs\": [\n",
    "                {\n",
    "                    \"name\": \"textItems\",\n",
    "                    \"targetName\": \"pages\"\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "\n",
    "key_phrase_extraction_skill = {\n",
    "            \"@odata.type\": \"#Microsoft.Skills.Text.KeyPhraseExtractionSkill\",\n",
    "            \"context\": \"/document/pages/*\",\n",
    "            \"inputs\": [\n",
    "                {\n",
    "                    \"name\": \"text\", \n",
    "                    \"source\": \"/document/pages/*\"\n",
    "                },\n",
    "                {\n",
    "                    \"name\": \"languageCode\", \n",
    "                    \"source\": \"/document/languageCode\"\n",
    "                }\n",
    "            ],\n",
    "            \"outputs\": [\n",
    "                {\n",
    "                    \"name\": \"keyPhrases\",\n",
    "                    \"targetName\": \"keyPhrases\"\n",
    "                }\n",
    "            ]\n",
    "        }\n",
    "\n",
    "\n",
    "skill_list = [language_detection_skill, text_split_skill]\n",
    "\n",
    "skillset_payload = {\n",
    "    \"name\": skillset_name,\n",
    "    \"description\": \"Detect language, split text and extract key-phrases\",\n",
    "    \"skills\": skill_list    \n",
    "}\n",
    "\n",
    "r = requests.put(endpoint + \"/skillsets/\" + skillset_name,\n",
    "                 data=json.dumps(skillset_payload), headers=headers, params=params)\n",
    "                 \n",
    "print(r.status_code)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create custom skill \n",
    "\n",
    "To separate sections of the text\n",
    "\n",
    "Create custom skill https://docs.microsoft.com/en-us/azure/search/cognitive-search-custom-skill-python\n",
    "\n",
    "About custom skills https://docs.microsoft.com/en-us/azure/search/cognitive-search-custom-skill-interface\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3. Create an index\n",
    "\n",
    "Define index schema by specifying the fields to include in the searchable index and setting the search attributes for each field. \n",
    "\n",
    "Indexes -> https://docs.microsoft.com/en-us/rest/api/searchservice/create-index\n",
    "\n",
    "https://docs.microsoft.com/en-us/azure/search/search-howto-indexing-azure-blob-storage"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_field(name:str, type:str, searchable=\"false\", filterable=\"false\", sortable=\"false\", facetable=\"false\", key=\"false\") -> dict:\n",
    "    field = {\n",
    "            \"name\": name,\n",
    "            \"type\": type,\n",
    "            \"key\": key,\n",
    "            \"searchable\": searchable,\n",
    "            \"filterable\": filterable,\n",
    "            \"sortable\": sortable,\n",
    "            \"facetable\": facetable\n",
    "        }\n",
    "    \n",
    "    return field\n",
    "\n",
    "id_field = create_field(name=\"id\", type=\"Edm.String\", searchable=\"true\", sortable=\"true\", key=\"true\")\n",
    "content_field = create_field(name=\"content\", type=\"Edm.String\", searchable=\"true\")\n",
    "language_code_field = create_field(name=\"languageCode\", type=\"Edm.String\", searchable=\"true\", filterable=\"true\")\n",
    "key_phrases_field = create_field(name=\"keyPhrases\", type=\"Collection(Edm.String)\",  searchable=\"true\")\n",
    "\n",
    "#metadata \n",
    "metadata_author_field = create_field(name=\"authors\", type=\"Edm.String\", searchable=\"true\")\n",
    "metadata_title_field = create_field(name=\"title\", type=\"Edm.String\", searchable=\"true\", sortable=\"true\")\n",
    "metadata_creation_date_field = create_field(name=\"creationDate\", type=\"Edm.String\", sortable=\"true\", filterable=\"true\")\n",
    "\n",
    "metadata_storage_name = create_field(name=\"storageName\", type=\"Edm.String\", searchable=\"true\", sortable=\"true\")\n",
    "metadata_storage_size = create_field(name=\"storageSize\", type=\"Edm.Int64\", sortable=\"true\", filterable=\"true\")\n",
    "\n",
    "fields_list = [id_field, content_field, language_code_field, key_phrases_field, metadata_author_field, metadata_title_field, metadata_creation_date_field, metadata_storage_name, metadata_storage_size]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "201\n"
     ]
    }
   ],
   "source": [
    "index_payload = {\n",
    "    \"name\": index_name,\n",
    "    \"fields\": fields_list\n",
    "}\n",
    "\n",
    "r = requests.put(endpoint + \"/indexes/\" + index_name, \n",
    "                data=json.dumps(index_payload), headers=headers, params=params)\n",
    "\n",
    "print(r.status_code)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 4. Create an indexer\n",
    "\n",
    "Indexers drive the pipeline. Creating an indexer puts the pipeline in motion.\n",
    "\n",
    "All the above 3 components (data source, skillset and index) are inputs for the indexer. \n",
    "\n",
    "-> how to field map https://docs.microsoft.com/en-us/azure/search/search-indexer-field-mappings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "201\n"
     ]
    }
   ],
   "source": [
    "indexer_payload = {\n",
    "    \"name\": indexer_name,\n",
    "    \"description\": None,\n",
    "    \"dataSourceName\": datasource_name,\n",
    "    \"targetIndexName\": index_name,\n",
    "    \"skillsetName\": skillset_name,\n",
    "    \"fieldMappings\": [\n",
    "        {\n",
    "            \"sourceFieldName\": \"metadata_storage_path\",\n",
    "            \"targetFieldName\": \"id\",\n",
    "            \"mappingFunction\":\n",
    "            {\"name\": \"base64Encode\"}\n",
    "        },\n",
    "        {\n",
    "            \"sourceFieldName\": \"content\",\n",
    "            \"targetFieldName\": \"content\"\n",
    "        }, \n",
    "        {\n",
    "            \"sourceFieldName\": \"metadata_storage_size\",\n",
    "            \"targetFieldName\": \"storageSize\"\n",
    "        }, \n",
    "        {\n",
    "            \"sourceFieldName\": \"metadata_storage_name\",\n",
    "            \"targetFieldName\": \"storageName\"\n",
    "        }, \n",
    "        {\n",
    "            \"sourceFieldName\": \"metadata_title\", \n",
    "            \"targetFieldName\": \"title\"\n",
    "        }, \n",
    "        {\n",
    "            \"sourceFieldName\": \"metadata_creation_date\",\n",
    "            \"targetFieldName\": \"creationDate\"   # doesn't ~always~ work\n",
    "        },\n",
    "        {\n",
    "            \"sourceFieldName\": \"metadata_author\",\n",
    "            \"targetFieldName\": \"authors\"        # doesn't work well. It depends how the authors are separated in the metadata\n",
    "        }\n",
    "    ],\n",
    "    \"outputFieldMappings\":\n",
    "    [\n",
    "        {\n",
    "            \"sourceFieldName\": \"/document/pages/*/keyPhrases/*\",\n",
    "            \"targetFieldName\": \"keyPhrases\"\n",
    "        },\n",
    "        {\n",
    "            \"sourceFieldName\": \"/document/languageCode\",\n",
    "            \"targetFieldName\": \"languageCode\"\n",
    "        }\n",
    "    ],\n",
    "    \"parameters\":\n",
    "    {\n",
    "        \"maxFailedItems\": -1, #ignore errors during data import\n",
    "        \"maxFailedItemsPerBatch\": -1,\n",
    "        \"configuration\":\n",
    "        {\n",
    "            \"dataToExtract\": \"contentAndMetadata\"\n",
    "        }\n",
    "    }\n",
    "}\n",
    "\n",
    "r = requests.put(endpoint + \"/indexers/\" + indexer_name,\n",
    "                 data=json.dumps(indexer_payload), headers=headers, params=params)\n",
    "print(r.status_code)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Get indexer status\n",
    "#r = requests.get(endpoint + \"/indexers/\" + indexer_name +\n",
    "#                 \"/status\", headers=headers, params=params)\n",
    "#pprint(json.dumps(r.json(), indent=1))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 5. Search\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "Not needed now necessarily -> How to page results: https://docs.microsoft.com/en-us/azure/search/search-pagination-page-layout"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Verification step: get the index definition of all fields\n",
    "\n",
    "#r = requests.get(endpoint + \"/indexes/\" + index_name, headers=headers, params=params)\n",
    "#pprint(json.dumps(r.json(), indent=1))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Query the index to return the contents of a single field -> content\n",
    "time.sleep(10)\n",
    "\n",
    "r = requests.get(endpoint + \"/indexes/\" + index_name + \"/docs?&search=*&$count=true&$select=content\", headers=headers, params=params)\n",
    "\n",
    "result_json = r.json()\n",
    "\n",
    "#result = json.dumps(result_json, indent=1)\n",
    "\n",
    "#pprint(result)\n",
    "document_count = result_json[\"@odata.count\"]\n",
    "article_list = []\n",
    "\n",
    "for i in range(document_count):\n",
    "    article_list.append(result_json[\"value\"][i])\n",
    "    \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "O R I G I N A L A R T I C L E\n",
      "\n",
      "Self-reported olfactory loss associates with outpatient clinical course\n",
      "in COVID-19\n",
      "\n",
      "Carol H. Yan, MD1 , Farhoud Faraji, MD, PhD1, Divya P. Prajapati, BS1,2, Benjamin T. Ostrander, MD1 and\n",
      "Adam S. DeConde, MD1\n",
      "\n",
      "Background: Rapid spread of the severe acute respiratory\n",
      "syndrome-coronavirus-2 (SARS-CoV-2) virus has le� many\n",
      "health systems around the world overwhelmed, forcing\n",
      "triaging of scarce medical resources. Identifying indicators\n",
      "of hospital admission for coronavirus disease 2019 (COVID-\n",
      "19) patients early in the disease course could aid the ef-\n",
      "ficient allocation of medical interventions. Self-reported\n",
      "olfactory impairment has recently been recognized as a\n",
      "hallmark of COVID-19 and may be an important predictor\n",
      "of clinical outcome.\n",
      "\n",
      "Methods: A retrospective review of all patients pre-\n",
      "senting to a San Diego Hospital system with laboratory-\n",
      "confirmed positive COVID-19 infection was conducted with\n",
      "evaluation of olfactory and gustatory function and clinical\n",
      "disease course. Univariable and multivariable logistic re-\n",
      "gression were performed to identify risk factors for hos-\n",
      "pital admission and anosmia.\n",
      "\n",
      "Results: A total of 169 patients tested positive for COVID-\n",
      "19 disease between March 3 and April 8, 2020. Olfactory\n",
      "and gustatory data were obtained for 128 (75.7%) of 169\n",
      "subjects, of which 26 (20.1%) of 128 required hospitaliza-\n",
      "tion. Admission for COVID-19 was associated with intact\n",
      "\n",
      "sense of smell and taste, increased age, diabetes, and sub-\n",
      "jective and objective parameters associated with respira-\n",
      "tory failure. On adjusted analysis, anosmia was strongly and\n",
      "independently associated with outpatient care (adjusted\n",
      "odds ratio [aOR] 0.09; 95% CI, 0.01-0.74), whereas positive\n",
      "findings of pulmonary infiltrates and/or pleural effusion on\n",
      "chest radiograph (aOR 8.01; 95% CI, 1.12-57.49) was strongly\n",
      "and independently associated with admission.\n",
      "\n",
      "Conclusion: Normosmia is an independent predictor of ad-\n",
      "mission in COVID-19 cases. Smell loss in COVID-19 may be\n",
      "associated with a milder clinical course. C© 2020 ARS-AAOA,\n",
      "LLC.\n",
      "\n",
      "Key Words:\n",
      "COVID-19; smell loss; taste loss; patient outcomes; admis-\n",
      "sion; hospitalization\n",
      "\n",
      "How to Cite this Article:\n",
      "Yan CH, Faraji F, Prajapati DP, Ostrander BT, DeConde\n",
      "AS. Self-reported olfactory loss associates with outpa-\n",
      "tient clinical course inCOVID-19. Int Forum Allergy Rhinol.\n",
      "2020;10:821–831.\n",
      "\n",
      "T he rapid worldwide spread of the coronavirus dis-\n",
      "ease 2019 (COVID-19) pandemic has placed an un-\n",
      "\n",
      "1Department of Surgery, Division of Otolaryngology–Head and Neck\n",
      "Surgery, University of California San Diego Health, La Jolla, CA;\n",
      "2School of Medicine, University of California San Diego, La Jolla, CA\n",
      "\n",
      "Correspondence to: Carol H. Yan, MD, Department of Surgery, Division of\n",
      "Otolaryngology–Head and Neck Surgery, University of California San Diego,\n",
      "9350 Campus Point Drive, Mail Code 0970, La Jolla, CA 92037; e-mail:\n",
      "c1yan@health.ucsd.edu\n",
      "\n",
      "Additional supporting information may be found online in the Supporting\n",
      "Information section at the end of the article.\n",
      "Funding sources for the study: National Institutes of Health (Clinical and\n",
      "Translational Science Awards [CTSA], UL1TR001442).\n",
      "Potential conflict of interest: A.S.D. is a consultant for Stryker Endoscopy,\n",
      "Olympus, IntersectENT, Sanofi, and Optinose. The other authors have no\n",
      "financial disclosures.\n",
      "\n",
      "Received: 18 April 2020; Revised: 21 April 2020; Accepted: 21 April 2020\n",
      "DOI: 10.1002/alr.22592\n",
      "View this article online at wileyonlinelibrary.com.\n",
      "\n",
      "precedented strain on hospitals and healthcare systems.1\n",
      "\n",
      "Severe acute respiratory syndrome-coronavirus-2 (SARS-\n",
      "CoV-2), the virus mediating COVID-19, continues to af-\n",
      "fect individuals of all ages, ranging from asymptomatic\n",
      "to fatal infection.2-7 Recent examples of overwhelmed\n",
      "healthcare systems underline the urgent need for develop-\n",
      "ing strategies to predict early symptoms and disease tra-\n",
      "jectory with biomarkers and clinical prognosticators.8 A\n",
      "cost-effective method of early risk stratification of disease\n",
      "severity would enable improved medical decision-making,\n",
      "rapid and severity-appropriate intervention, and facilitate\n",
      "the allocation of limited medical resources. Under such a\n",
      "paradigm, patients found to carry markers associated with\n",
      "severe manifestations of COVID-19 would be considered\n",
      "high-risk and monitored closely for further escalation of\n",
      "care. Meanwhile, those displaying markers associated with\n",
      "low-risk disease could be recommended to self-monitor\n",
      "\n",
      "International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020 821\n",
      "\n",
      "https://orcid.org/0000-0003-1934-4922\n",
      "http://crossmark.crossref.org/dialog/?doi=10.1002%2Falr.22592&domain=pdf&date_stamp=2020-06-07\n",
      "\n",
      "\n",
      "Yan et al.\n",
      "\n",
      "under quarantine conditions, allowing health systems to\n",
      "conserve scarce resources for impending COVID-19 case\n",
      "surges or the care of non–COVID-19 patients.\n",
      "\n",
      "Olfactory and gustatory dysfunction have recently been\n",
      "found to be associated with COVID-19 infection.9-12 The\n",
      "growing number of Internet searches inquiring about loss\n",
      "of smell strongly correlates with the increased prevalence\n",
      "of COVID-19.13 In ambulatory populations, patients who\n",
      "present with influenza-like symptoms and anosmia are 6\n",
      "to 10 times more likely to test positive for COVID-19\n",
      "infection.9,10 Indeed, 59% to 86% of outpatient COVID-19\n",
      "positive patients self-reported olfactory loss.9,10,12 Notably,\n",
      "self-reported anosmia in COVID-19–positive hospitalized\n",
      "patients has also been identified as a common symptom,\n",
      "but is consistently reported at lower rates in this popula-\n",
      "tion (5-35%).11,14,15 Although limited quantitative olfac-\n",
      "tory data exist in either outpatient or inpatient contexts,\n",
      "early findings in inpatients with COVID-19 suggest that\n",
      "only 28% self-reported smell loss and a minority (25%)\n",
      "demonstrated complete anosmia, despite some degree of\n",
      "measurable olfactory dysfunction in almost all subjects.11\n",
      "\n",
      "In contrast, in an outpatient managed cohort of COVID-19\n",
      "subjects, the self-reported severity and incidence of olfac-\n",
      "tory dysfunction was high, with most patients reporting a\n",
      "profound and complete loss of smell (0/10).9 Comparing\n",
      "the prevalence of self-reported smell loss between mild or\n",
      "ambulatory cases and moderate to severe inpatient cases of\n",
      "COVID-19 may provide insights into an individual’s dis-\n",
      "ease prognosis. This study sought to investigate the associa-\n",
      "tion between self-reported anosmia and hospital admission\n",
      "during the course of COVID-19.\n",
      "\n",
      "Subjects and methods\n",
      "Study design and population\n",
      "\n",
      "A retrospective analysis of all adult subjects presenting to\n",
      "the UC San Diego Health System (Jacobs and Hillcrest\n",
      "Medical Centers) with confirmed polymerase chain reaction\n",
      "(PCR)-positive testing for the SARS-CoV-2 viral nucleic\n",
      "acid from nasopharyngeal swabs was done. Demographic\n",
      "data (Table 1) along with subjective and objective clini-\n",
      "cal data (Table 2) were obtained from review of electronic\n",
      "medical records (EMR), specifically encounters pertaining\n",
      "to COVID-19 diagnosis. Self-reported sense of smell and\n",
      "taste during time of illness were compared to premorbid\n",
      "levels as dichotomous variables (loss of smell/taste vs nor-\n",
      "mal/baseline). Specifically, we first retrospectively queried\n",
      "the EMR for assessments on olfactory/gustatory function in\n",
      "the encounters related to COVID-19. If self-reported olfac-\n",
      "tory/gustatory function data were not available in the EMR,\n",
      "we emailed or called patients to inquire about the status of\n",
      "olfactory and gustatory function (“Have you had any smell\n",
      "loss during this period of illness compared to before?” and\n",
      "“Have you had any taste loss during this illness compared\n",
      "to before?”). Chest radiograph findings were categorized\n",
      "as “negative” if no findings were present and defined as\n",
      "\n",
      "TABLE 1. Baseline characteristics: comparison of\n",
      "demographic and baseline clinical characteristics in\n",
      "\n",
      "admitted and ambulatory COVID-19–positive subjects\n",
      "\n",
      "Characteristic\n",
      "\n",
      "COVID-19–\n",
      "\n",
      "positive\n",
      "\n",
      "Admitted\n",
      "\n",
      "(n = 26)\n",
      "\n",
      "COVID-19–\n",
      "\n",
      "positive\n",
      "\n",
      "Ambulatory\n",
      "\n",
      "(n = 102) p\n",
      "a\n",
      "\n",
      "Baseline characteristics\n",
      "\n",
      "Age (years), median (IQR)\n",
      "b\n",
      "\n",
      "53.5 (40–65) 43 (34–54) 0.0093\n",
      "\n",
      "Gender, n (%)\n",
      "\n",
      "Male 9 (34.6) 52 (51) 0.14\n",
      "\n",
      "Female 17 (65.4) 50 (49)\n",
      "\n",
      "Race, n (%)\n",
      "\n",
      "White 8 (30.8) 50 (49) 0.29\n",
      "\n",
      "Black 3 (11.5) 5 (4.9)\n",
      "\n",
      "Hispanic 7 (26.9) 21 (20.6)\n",
      "\n",
      "Asian 4 (15.4) 7 (6.9)\n",
      "\n",
      "Other/mixed 4 (15.4) 13 (12.8)\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "BMI (kg/m2), median (IQR)\n",
      "b\n",
      "\n",
      "28.4\n",
      "(25.7–31.2)\n",
      "\n",
      "25.9\n",
      "(23.1–29.7)\n",
      "\n",
      "0.11\n",
      "\n",
      "Tobacco use, n (%)\n",
      "\n",
      "Never smoker 22 (84.6) 79 (77.5) 0.87\n",
      "\n",
      "Current/recent smoker 4 (15.4) 13 (12.8)\n",
      "\n",
      "Unknown/missing 0 10 (9.8)\n",
      "\n",
      "Past medical history, n (%)\n",
      "\n",
      "Hypertension\n",
      "\n",
      "No 19 (73.1) 81 (79.4) 0.18\n",
      "\n",
      "Yes 7 (26.9) 15 (14.7)\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "Diabetes mellitus\n",
      "\n",
      "No 18 (69.2) 90 (88.2) 0.001\n",
      "\n",
      "Yes 8 (30.8) 6 (5.9)\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "COPD\n",
      "\n",
      "No 26 (100) 92 (90.2) 0.29\n",
      "\n",
      "Yes 0 4 (3.9)\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "Asthma\n",
      "\n",
      "No 23 (88.5) 86 (84.3) 0.87\n",
      "\n",
      "Yes 3 (11.5) 10 (9.8)\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "(Continued)\n",
      "\n",
      "822 International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020\n",
      "\n",
      "\n",
      "\n",
      "Smell loss linked to milder form of COVID-19\n",
      "\n",
      "TABLE 1. Continued\n",
      "\n",
      "Characteristic\n",
      "\n",
      "COVID-19–\n",
      "\n",
      "positive\n",
      "\n",
      "Admitted\n",
      "\n",
      "(n = 26)\n",
      "\n",
      "COVID-19–\n",
      "\n",
      "positive\n",
      "\n",
      "Ambulatory\n",
      "\n",
      "(n = 102) p\n",
      "a\n",
      "\n",
      "Sinusitis\n",
      "c\n",
      "\n",
      "No 26 (100) 91 (89.2) 0.24\n",
      "\n",
      "Yes 0 5 (4.9)\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "Cardiovascular disease\n",
      "\n",
      "No 23 (88.5) 91 (89.2) 0.25\n",
      "\n",
      "Yes 3 (11.5) 5 (4.9)\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "Chronic kidney disease\n",
      "\n",
      "No 24 (92.3) 94 (92.2) 0.15\n",
      "\n",
      "Yes 2 (7.7) 2(2.0)\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "Cancer\n",
      "\n",
      "No 25 (96.2) 91 (89.2) 0.78\n",
      "\n",
      "Yes 1 (3.8) 5 (4.9)\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "HIV/other immunosuppression\n",
      "\n",
      "No 24 (92.3) 82 (80.4) 0.41\n",
      "\n",
      "Yes 2 (7.7) 13 (12.8)\n",
      "\n",
      "Unknown/missing 0 7 (6.9)\n",
      "\n",
      "Obstructive sleep apnea\n",
      "\n",
      "No 25 (96.2) 93 (91.2) 0.86\n",
      "\n",
      "Yes 1 (3.8) 3 (2.9)\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "Stroke\n",
      "\n",
      "No 23 (88.5) 96 (94.1) 0.001\n",
      "\n",
      "Yes 3 (11.5) 0\n",
      "\n",
      "Unknown/missing 0 6 (5.9)\n",
      "\n",
      "aValues of p determined by chi-square test unless otherwise specified, unknowns\n",
      "excluded in statistical testing.\n",
      "bStudent 2-way t test.\n",
      "cChronic rhinosinusitis or currently experiencing acute episode of rhinosinusitis.\n",
      "BMI = body mass index; COVID-19 = coronavirus 2019; COPD = chronic obstruc-\n",
      "tive pulmonary disease; HIV = human immunodeficiency virus; IQR = interquartile\n",
      "range.\n",
      "\n",
      "“positive” if presence of pulmonary infiltrates and/or pleu-\n",
      "ral effusions were reported on final read by the attending\n",
      "radiologist. This study was approved by the Institutional\n",
      "Review Board of University of California San Diego (IRB\n",
      "#200485).\n",
      "\n",
      "Statistical analysis\n",
      "Statistical analysis was conducted with Stata 15.1 software\n",
      "(StataCorp, College Station, TX). The primary outcome\n",
      "was hospital admission. The secondary outcome was anos-\n",
      "mia. Descriptive comparisons stratified by hospital admis-\n",
      "sion and anosmia were conducted using a chi-square (χ2)\n",
      "test for categorical data and 2-way Student t test for con-\n",
      "tinuous variables. The threshold for statistical significance\n",
      "was set at p < 0.05. Multivariable logistic regression mod-\n",
      "els were built to identify independent patient characteristics\n",
      "associated with hospital admission as the dependent vari-\n",
      "able. Logistic regression was also performed with anosmia\n",
      "as the dependent variable. Inclusion criteria for factor inclu-\n",
      "sion in multivariable models were set a priori and included\n",
      "variables with the strongest magnitudes of association and\n",
      "lowest probability of type I error on univariable logistic\n",
      "regression. A maximum of 8 variables were included to\n",
      "minimize potential model overfitting. Given the known co-\n",
      "linear relationship between anosmia and dysgeusia, analy-\n",
      "ses focused on anosmia alone. Similarly, analyses involving\n",
      "decision to admit and decision to obtain a chest radiograph\n",
      "focused on decision to admit; these variables were thus also\n",
      "considered colinear. Although anosmia is not plausibly de-\n",
      "pendent upon hospital admission, hospital admission was\n",
      "kept in the multivariable model investigating associations\n",
      "with anosmia as a marker for overall disease severity. Dis-\n",
      "tribution medians with interquartile ranges (IQRs), odds\n",
      "ratios (ORs; univariable logistic regression), adjusted odds\n",
      "ratios (aORs; multivariable logistic regression), and 95%\n",
      "confidence intervals (CIs) were reported with correspond-\n",
      "ing probabilities of type-I error (p value).\n",
      "\n",
      "Results\n",
      "Clinical characteristics\n",
      "\n",
      "A total of 169 patients tested positive for COVID-19 infec-\n",
      "tion between March 3, 2020, and April 8, 2020. Smell and\n",
      "taste data were available for 128 subjects (75.7%) who\n",
      "were included in the final study cohort. Patients without\n",
      "smell and taste data included those who were deceased\n",
      "(3/169; 1.7%) or intubated (6/169; 3.5%) at the close of\n",
      "data collection, were recently hospitalized with incomplete\n",
      "admission data (4/169; 2.4%), or could not be reached or\n",
      "declined to participate in the study and had no smell or\n",
      "taste information recorded in the medical record (28/169;\n",
      "16.6%). The demographics and baseline clinical charac-\n",
      "teristics of the study participants are described in Table 1.\n",
      "Table 2 reports the cohort’s subjective and objective clinical\n",
      "findings at presentation.\n",
      "\n",
      "Twenty-six (20.1%) of 128 patients were admitted for\n",
      "management of COVID-19. Patients who were admitted\n",
      "were significantly less likely to report anosmia/hyposmia\n",
      "(26.9% vs 66.7%, p < 0.001) and dysgeusia (23.1% vs\n",
      "62.7%, p < 0.001) than those who were managed as out-\n",
      "patients. Beyond the symptoms of anosmia/hyposmia and\n",
      "dysgeusia, age (median 53.5 years [IQR, 40-65 years] vs\n",
      "\n",
      "International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020 823\n",
      "\n",
      "\n",
      "\n",
      "Yan et al.\n",
      "\n",
      "TABLE 2. COVID-19–associated clinical findings: comparison of subjective and objective clinical findings in admitted and\n",
      "ambulatory COVID-19–positive subjects\n",
      "\n",
      "Parameter COVID-19–positive Admitted (n = 26) COVID-19–positive Ambulatory (n = 102) p\n",
      "a\n",
      "\n",
      "Subjective clinical findings\n",
      "\n",
      "Days symptomatic prior to COVID-19 test, median (IQR)\n",
      "b\n",
      "\n",
      "4 (2–7) 5.5 (3–8) 0.39\n",
      "\n",
      "Anosmia/hyposmia, n (%) <0.001\n",
      "\n",
      "No 19 (73.1) 34 (33.3)\n",
      "\n",
      "Yes 7 (26.9) 68 (66.7)\n",
      "\n",
      "Dysgeusia, n (%) <0.001\n",
      "\n",
      "No 19 (73.1) 31 (30.4)\n",
      "\n",
      "Yes 6 (23.1) 64 (62.7)\n",
      "\n",
      "Unknown/missing 1 (3.8) 7 (6.9)\n",
      "\n",
      "Fatigue, n (%) 0.19\n",
      "\n",
      "No 5 (19.2) 33 (32.4)\n",
      "\n",
      "Yes 21 (80.8) 69 (67.6)\n",
      "\n",
      "Diarrhea, n (%)\n",
      "\n",
      "No 12 (46.2) 68 (66.7) 0.054\n",
      "\n",
      "Yes 14 (53.8) 34 (33.3)\n",
      "\n",
      "Fever, n (%) 0.074\n",
      "\n",
      "No 4 (15.4) 34 (33.3)\n",
      "\n",
      "Yes 22 (84.6) 68 (66.7)\n",
      "\n",
      "Cough, n (%) 0.14\n",
      "\n",
      "No 1 (3.8) 15 (14.7)\n",
      "\n",
      "Yes 25 (96.2) 87 (85.3)\n",
      "\n",
      "Dyspnea, n (%) 0.002\n",
      "\n",
      "No 6 (23.1) 58 (56.9)\n",
      "\n",
      "Yes 20 (76.9) 44 (43.1)\n",
      "\n",
      "Sputum production, n (%) 0.03\n",
      "\n",
      "No 11 (42.3) 53 (51.9)\n",
      "\n",
      "Yes 8 (30.8) 12 (11.8)\n",
      "\n",
      "Unknown/missing 7 (26.9) 37 (36.3)\n",
      "\n",
      "Sore throat, n (%) 0.34\n",
      "\n",
      "No 17 (65.4) 56 (54.9)\n",
      "\n",
      "Yes 9 (34.6) 46 (45.1)\n",
      "\n",
      "Headache, n (%) 0.86\n",
      "\n",
      "No 13 (50.0) 53 (51.9)\n",
      "\n",
      "Yes 13 (50.0) 49 (48.1)\n",
      "\n",
      "Rhinorrhea, n (%) 0.11\n",
      "\n",
      "No 25 (96.2) 86 (84.3)\n",
      "\n",
      "Yes 1 (3.8) 16 (15.7)\n",
      "\n",
      "(Continued)\n",
      "\n",
      "824 International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020\n",
      "\n",
      "\n",
      "\n",
      "Smell loss linked to milder form of COVID-19\n",
      "\n",
      "TABLE 2. Continued\n",
      "\n",
      "Parameter COVID-19–positive Admitted (n = 26) COVID-19–positive Ambulatory (n = 102) p\n",
      "a\n",
      "\n",
      "Nasal obstruction/thick discharge, n (%) 0.13\n",
      "\n",
      "No 22 (84.6) 71 (69.6)\n",
      "\n",
      "Yes 4 (15.4) 31 (30.4)\n",
      "\n",
      "Objective clinical findings\n",
      "\n",
      "Temperature, median (IQR)\n",
      "b\n",
      "\n",
      "99.8 (99–101.4) 98.6 (98.3–99) <0.001\n",
      "\n",
      "Heart rate, median (IQR)\n",
      "b\n",
      "\n",
      "95.5 (83–106) 83 (75–96) 0.004\n",
      "\n",
      "Respiratory rate, median (IQR)\n",
      "b\n",
      "\n",
      "19 (18–23) 18 (16–18) <0.001\n",
      "\n",
      "Blood oxygen saturation, median (IQR)\n",
      "b\n",
      "\n",
      "96 (94–98) 98 (95–100) 0.77\n",
      "\n",
      "Total leukocyte count, median (IQR)\n",
      "b\n",
      "\n",
      "6.5 (5.7–9.4) 4.9 (3–5.4) 0.012\n",
      "\n",
      "Lymphocyte count, median (IQR)\n",
      "b\n",
      "\n",
      "1.1 (0.6–13) 1.8 (0.9–24) 0.41\n",
      "\n",
      "Serum creatinine, median (IQR)\n",
      "b\n",
      "\n",
      "0.8 (0.6–1.0) 0.9 (0.8–0.9) 0.34\n",
      "\n",
      "Serum AST, median (IQR)\n",
      "b\n",
      "\n",
      "44 (28–68) 34 (27–51) 0.14\n",
      "\n",
      "Serum ALT, median (IQR)\n",
      "b\n",
      "\n",
      "32 (20–82) 31 (23–44) 0.15\n",
      "\n",
      "Serum lactate, median (IQR)\n",
      "b\n",
      "\n",
      "1.9 (1.5–2.2) 1.4 (1.1–1.9) 0.43\n",
      "\n",
      "Chest radiograph performed, n (%) <0.001\n",
      "\n",
      "No 2 (7.7) 64 (62.7)\n",
      "\n",
      "Yes 24 (92.3) 35 (34.3)\n",
      "\n",
      "Unknown/missing 0 3 (2.9)\n",
      "\n",
      "Chest radiograph findings, n (%)\n",
      "c\n",
      "\n",
      "<0.001\n",
      "\n",
      "Negative 2 (7.7) 20 (19.6)\n",
      "\n",
      "Positive 23 (88.5) 15 (14.7)\n",
      "\n",
      "No chest radiograph 1 (3.8) 67 (65.7)\n",
      "\n",
      "aValue of p determined by chi-square test, unless otherwise specified, unknowns excluded in statistical test.\n",
      "bValue of p determined by t test.\n",
      "cPositive findings include pulmonary infiltrates and/or pleural effusion.\n",
      "ALT = alanine aminotransferase; AST = aspartate aminotransferase; COVID-19 = coronavirus 2019; IQR = interquartile range.\n",
      "\n",
      "43.0 years [IQR, 34-54 years], p = 0.009) and diabetes\n",
      "(30.1% vs 5.9%, p = 0.001) were associated with ad-\n",
      "mission. Clinical subjective and objective characteristics\n",
      "associated with respiratory failure at the time of presen-\n",
      "tation were also associated with admission (Table 2).\n",
      "Specifically, admitted patients more frequently reported\n",
      "dyspnea (76.9% vs 43.1%, p = 0.002) and sputum\n",
      "production (30.8% vs 11.8%, p = 0.03), and exhibited\n",
      "elevated respiratory rate (median 19 [IQR, 18-23] vs 18\n",
      "[IQR, 16-18], p < 0.001) and body temperature (median\n",
      "99.8°C [IQR, 99.0°C to 101.4°C] vs 98.6°C [IQR, 98.3°C\n",
      "to 99.0°C], p < 0.001). Both the decision to obtain a\n",
      "chest radiograph (92.3% vs 34.3%, p < 0.001) as well\n",
      "as the presence of positive findings (88.5% vs 14.7%,\n",
      "p < 0.001) were more commonly found in the patients\n",
      "who were ultimately admitted. Further data profiling the\n",
      "admitted cohort, but not applicable to comparisons with\n",
      "an outpatient cohort, is included in Supporting Table 1.\n",
      "\n",
      "Regression analysis\n",
      "On univariable logistic regression anosmia/hyposmia was\n",
      "found to be inversely related to hospital admission in\n",
      "COVID-19 patients; patients reporting anosmia/hyposmia\n",
      "were 5-fold more likely to be managed in the outpatient\n",
      "setting (OR 0.20; 95% CI, 0.06-0.64). Other factors as-\n",
      "sociated with hospital admission included age (OR 1.04;\n",
      "95% CI, 1.01-1.07), diabetes mellitus (OR 6.67; 95% CI,\n",
      "2.06-21.55), dyspnea (OR 4.39; 95% CI, 1.63-11.86), spu-\n",
      "tum production (OR 3.21; 95% CI, 1.81-9.70), tempera-\n",
      "ture (OR 2.33; 95% CI, 1.52-3.59), heart rate (OR 1.04;\n",
      "95% CI, 1.01-1.07), respiratory rate (OR 1.04; 95% CI,\n",
      "1.01-1.07), whether chest radiograph was performed (OR\n",
      "21.94; 95% CI, 4.90-98.36), and chest radiograph findings\n",
      "positive for infiltrates and/or pleural effusion (OR 20.91;\n",
      "95% CI, 4.13-105.81; Table 3).\n",
      "\n",
      "Multivariable logistic regression adjusting for factors as-\n",
      "sociated with admission on univariable analysis showed\n",
      "\n",
      "International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020 825\n",
      "\n",
      "\n",
      "\n",
      "Yan et al.\n",
      "\n",
      "TABLE 3. Clinical characteristics associated with admission for COVID-19\n",
      "*\n",
      "\n",
      "Characteristic Univariable regression OR (95% CI) p Multivariable regression aOR (95% CI) p\n",
      "\n",
      "Baseline characteristics\n",
      "\n",
      "Age, years 1.04 (1.01–1.07) 0.012 0.97 (0.90–1.04) 0.39\n",
      "\n",
      "Sex, male (Ref: female) 1.96 (0.80–4.81) 0.14\n",
      "\n",
      "Race (Ref: white) 1.17 (0.92–1.48) 0.2\n",
      "\n",
      "BMI (kg/m2) 1.07 (0.98–1.17) 0.11\n",
      "\n",
      "Tobacco use 1.10 (0.33–3.73) 0.87\n",
      "\n",
      "Past medical history\n",
      "\n",
      "Hypertension 1.99 (0.71–5.56) 0.19\n",
      "\n",
      "Diabetes mellitus 6.67 (2.06–21.55) 0.002 4.23 (0.34–52.52) 0.26\n",
      "\n",
      "COPD – –\n",
      "\n",
      "Asthma 1.12 (0.29–4.41) 0.87\n",
      "\n",
      "Sinusitis – –\n",
      "\n",
      "Cardiovascular disease 2.37 (0.53–10.67) 0.26\n",
      "\n",
      "Chronic kidney disease 3.92 (0.52–29.25) 0.18\n",
      "\n",
      "Cancer 0.73 (0.08–6.52) 0.78\n",
      "\n",
      "HIV/other immunosuppression 0.53 (0.11–2.49) 0.42\n",
      "\n",
      "Obstructive sleep apnea 1.24 (0.12–12.44) 0.86\n",
      "\n",
      "Stroke – –\n",
      "\n",
      "Subjective clinical findings\n",
      "\n",
      "Anosmia/hyposmia 0.20 (0.06–0.64) 0.007 0.09 (0.01–0.74) 0.025\n",
      "\n",
      "Fatigue 2.01 (0.70–5.80) 0.19\n",
      "\n",
      "Diarrhea 2.33 (0.97–5.59) 0.057\n",
      "\n",
      "Fever 2.75 (0.88–8.62) 0.083\n",
      "\n",
      "Cough 4.31 (0.54–34.25) 0.17\n",
      "\n",
      "Dyspnea 4.39 (1.63–11.86) 0.003 0.49 (0.08–3.13) 0.45\n",
      "\n",
      "Sputum production 3.21 (1.81–9.70) 0.039\n",
      "\n",
      "Sore throat 0.64 (0.26–1.58) 0.34\n",
      "\n",
      "Headache 1.08 (0.46–2.56) 0.86\n",
      "\n",
      "Rhinorrhea 0.22 (0.03–1.70) 0.15\n",
      "\n",
      "Nasal obstruction/thick discharge 0.42 (0.13–1.30) 0.13\n",
      "\n",
      "Objective clinical findings\n",
      "\n",
      "Temperature 2.33 (1.52–3.59) <0.001 2.40 (0.95–6.05) 0.063\n",
      "\n",
      "Heart rate 1.04 (1.01–1.07) 0.007 0.96 (0.90–1.04) 0.35\n",
      "\n",
      "Respiratory rate 1.46 (1.16–1.86) 0.002 1.34 (0.95–1.88) 0.09\n",
      "\n",
      "Blood oxygen saturation 0.99 (0.95–1.04) 0.77\n",
      "\n",
      "Total leukocyte count 1.50 (1.06–2.14) 0.023\n",
      "\n",
      "Lymphocyte count 0.98 (0.93–1.03) 0.41\n",
      "\n",
      "Serum creatinine 0.45 (0.09–2.33) 0.34\n",
      "\n",
      "(Continued)\n",
      "\n",
      "826 International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020\n",
      "\n",
      "\n",
      "\n",
      "Smell loss linked to milder form of COVID-19\n",
      "\n",
      "TABLE 3. Continued\n",
      "\n",
      "Characteristic Univariable regression OR (95% CI) p Multivariable regression aOR (95% CI) p\n",
      "\n",
      "Serum AST 1.02 (0.99–1.05) 0.16\n",
      "\n",
      "Serum ALT 1.02 (0.99–1.04) 0.18\n",
      "\n",
      "Serum lactate 5.41 (0.26–111.36) 0.27\n",
      "\n",
      "Chest radiograph performed 21.94 (4.90–98.36) <0.001\n",
      "\n",
      "Chest radiograph findings 20.91 (4.13–105.81) <0.001 8.01 (1.12–57.49) 0.039\n",
      "\n",
      "*Associations of baseline demographics and clinical findings of COVID-19 individuals with hospital admission were determined using univariable (reporting ORs) and\n",
      "multivariable (reporting aORs) logistic regression models. Dependent variable = admission.\n",
      "ALT = alanine aminotransferase; aOR = adjusted odds ratio; AST = aspartate aminotransferase; BMI = body mass index; CI = confidence interval; COPD = chronic\n",
      "obstructive pulmonary disease; COVID-19 = coronavirus 2019; HIV = human immunodeficiency virus; OR = odds ratio.\n",
      "\n",
      "that self-reported intact olfactory function and positive\n",
      "chest radiograph findings were the only factors indepen-\n",
      "dently associated with hospital admission. Notably, both\n",
      "smell loss and positive findings on chest radiograph showed\n",
      "clinically significant association strengths. Patients with\n",
      "anosmic/hyposmic COVID-19 were more than 10-fold less\n",
      "likely to be admitted than those with normosmic COVID-\n",
      "19 (aOR 0.09; 95% CI, 0.01-0.74). Patients with positive\n",
      "findings on chest radiograph were 8 times more likely to be\n",
      "admitted (aOR 8.01; 95% CI, 1.12-57.49), consistent with\n",
      "an expected clinical indicator of pulmonary disease and\n",
      "potentially impending respiratory failure requiring hospi-\n",
      "tal admission (Table 3).\n",
      "\n",
      "A multivariable analysis of independent predictors of\n",
      "anosmia revealed that anosmia was negatively associated\n",
      "with sputum production (aOR 0.26; 95% CI, 0.08-0.91).\n",
      "Hospital admission status was included in the model as a\n",
      "surrogate control for disease severity and, as was demon-\n",
      "strated in the primary analysis, showed a strong inverse re-\n",
      "lationship to anosmia/hyposmia (aOR 0.26; 95% CI, 0.07-\n",
      "0.96) (Table 4).\n",
      "\n",
      "Discussion\n",
      "Given the rapidly increasing number of COVID-19 cases\n",
      "that threaten to overwhelm healthcare systems, strategies\n",
      "to risk stratify patients and early determination of disease\n",
      "severity are urgently needed. Clinical characteristics asso-\n",
      "ciated with critical illness and mortality from COVID-19\n",
      "have been reported. A meta-analysis of clinical characteris-\n",
      "tics of over 40,000 COVID-19 patients from Wuhan found\n",
      "that patients with severe disease requiring intensive care\n",
      "were more likely to have comorbidities of hypertension\n",
      "(OR 2.36), respiratory system disease (OR 2.46), and car-\n",
      "diovascular disease (OR 3.42) compared to patient not re-\n",
      "quiring intensive care.16 Similar observations were made\n",
      "in Italy, with hypertension and coronary artery disease be-\n",
      "ing more prevalent in the severely ill COVID-19 patients.17\n",
      "\n",
      "Of critically ill patients, risk factors for mortality included\n",
      "increased age as a predictor of inpatient death (OR 1.1,\n",
      "or 10% increase with each additional year of age)18 along\n",
      "with markers of end-organ failure.17,18\n",
      "\n",
      "In addition to investigating markers of critical illness, it\n",
      "is important to consider characteristics that may help strat-\n",
      "ify mild and moderate infections in early-stage COVID-19.\n",
      "Here we present a novel clinical characteristic to help strat-\n",
      "ify mild from moderate disease early in SARS-CoV-2 in-\n",
      "fection. Patients reporting loss of smell were 10 times less\n",
      "likely to be admitted for COVID-19 (OR 0.09; 95% CI,\n",
      "0.01-0.74) compared to those without loss of smell. Fur-\n",
      "thermore, anosmia/hyposmia was not associated with any\n",
      "other measures typically related to the decision to admit,\n",
      "suggesting that smell loss is truly an independent correlate\n",
      "and may serve as a marker for milder manifestations of\n",
      "COVID-19.\n",
      "\n",
      "Our study’s findings are consistent with those of other\n",
      "studies evaluating both inpatient and outpatient self-\n",
      "reported olfactory dysfunction.9-12,14,15 Moein et al.11 re-\n",
      "ported very high rates of measured olfactory dysfunction\n",
      "(98%) on quantitative analysis of COVID-19 inpatients,\n",
      "but only 25% showed complete anosmia and 35% self-\n",
      "reported smell loss. This discrepancy between quantita-\n",
      "tive and self-reported olfactory dysfunction is thought to\n",
      "be related to a general unawareness or underreporting of\n",
      "hyposmia.19 In the COVID-19 inpatient population, de-\n",
      "creased awareness of chemosensory dysfunction may also\n",
      "be influenced by the presence of more severe symptoms\n",
      "such as respiratory distress. Despite this mismatch, we be-\n",
      "lieve that our study’s findings differentiating the incidence\n",
      "of smell loss between COVID-19 inpatients and outpatients\n",
      "are valuable, because self-reported loss may more closely re-\n",
      "flect profound or functional anosmia. Although the present\n",
      "study did not specifically investigate degree of smell loss,\n",
      "our previous study demonstrated that those who reported\n",
      "smell loss typically suffered from its complete absence (0\n",
      "out of 10 on a 0-10 scale).9 Although quantitative testing\n",
      "is more sensitive in detecting olfactory dysfunction, self-\n",
      "reporting of anosmia is relatively accurate (90%).19 Thus,\n",
      "our study suggests that milder cases of COVID-19 may be\n",
      "heralded by profound anosmia and higher self-reporting,\n",
      "compared to the undetected or mild hyposmia associated\n",
      "with moderate to severe COVID-19 cases. Further objec-\n",
      "tive olfactory testing of both outpatient and inpatient co-\n",
      "horts is required to clarify if quantitative differences in the\n",
      "\n",
      "International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020 827\n",
      "\n",
      "\n",
      "\n",
      "Yan et al.\n",
      "\n",
      "TABLE 4. Clinical characteristics associated with COVID-19–associated anosmia\n",
      "*\n",
      "\n",
      "Characteristic Univariable regression OR (95% CI) p Multivariable regression aOR (95% CI) p\n",
      "\n",
      "Baseline characteristics\n",
      "\n",
      "Age (years) 0.97 (0.95–0.99) 0.017 0.99 (0.96–1.03) 0.75\n",
      "\n",
      "Sex (Ref: female) 0.75 (0.37–1.51) 0.42\n",
      "\n",
      "Race (Ref: white) 0.93 (0.76–1.14) 0.47\n",
      "\n",
      "BMI (kg/m2) 1.03 (0.95–1.11) 0.52\n",
      "\n",
      "Tobacco use 1.06 (0.37–3.01) 0.91\n",
      "\n",
      "Admission 0.18 (0.07–0.48) 0.001 0.26 (0.07–0.96) 0.043\n",
      "\n",
      "Past medical history\n",
      "\n",
      "Hypertension 0.44 (0.17–1.13) 0.09\n",
      "\n",
      "Diabetes mellitus 0.52 (0.17–1.59) 0.25\n",
      "\n",
      "COPD 0.24 (0.02–2.34) 0.22\n",
      "\n",
      "Asthma 1.21 (0.37–3.95) 0.75\n",
      "\n",
      "Sinusitis 3.09 (0.34–25.50) 0.32\n",
      "\n",
      "Cardiovascular disease 1.26 (0.29–5.51) 0.76\n",
      "\n",
      "Chronic kidney disease 0.24 (0.02–2.34) 0.22\n",
      "\n",
      "Cancer 1.52 (0.27–8.60) 0.78\n",
      "\n",
      "HIV/other immunosuppression 0.62 (0.21–1.84) 0.39\n",
      "\n",
      "Obstructive sleep apnea 0.74 (0.10–5.39) 0.76\n",
      "\n",
      "Stroke 0.36 (0.03–4.11) 0.41\n",
      "\n",
      "Subjective clinical findings\n",
      "\n",
      "Fatigue 0.55 (0.25–1.23) 0.15\n",
      "\n",
      "Diarrhea 0.65 (0.32–1.35) 0.25\n",
      "\n",
      "Fever 0.55 (0.25–1.23) 0.15\n",
      "\n",
      "Cough 0.83 (0.28–2.44) 0.74\n",
      "\n",
      "Dyspnea 0.82 (0.41–1.67) 0.59\n",
      "\n",
      "Sputum production 0.26 (0.08–0.80) 0.019 0.26 (0.08–0.91) 0.034\n",
      "\n",
      "Sore throat 1.11 (0.54–2.26) 0.78\n",
      "\n",
      "Headache 1.43 (0.70–2.87) 0.34\n",
      "\n",
      "Rhinorrhea 1.01 (0.36–2.85) 0.98\n",
      "\n",
      "Nasal obstruction/thick discharge 2.59 (1.10–6.13) 0.03 2.44 (0.16–7.89) 0.14\n",
      "\n",
      "Objective clinical findings\n",
      "\n",
      "Temperature 0.73 (0.52–1.04) 0.08\n",
      "\n",
      "Heart rate 0.98 (0.96–1.01) 0.15\n",
      "\n",
      "Respiratory rate 0.88 (0.75–1.02) 0.08\n",
      "\n",
      "Blood oxygen saturation 0.99 (0.94–1.04) 0.62\n",
      "\n",
      "Total leukocyte count 0.87 (0.69–1.10) 0.24\n",
      "\n",
      "Lymphocyte count 0.99 (0.94–1.04) 0.75\n",
      "\n",
      "Serum creatinine 0.34 (0.04–2.62) 0.30\n",
      "\n",
      "(Continued)\n",
      "\n",
      "828 International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020\n",
      "\n",
      "\n",
      "\n",
      "Smell loss linked to milder form of COVID-19\n",
      "\n",
      "TABLE 4. Continued\n",
      "\n",
      "Characteristic Univariable regression OR (95% CI) p Multivariable regression aOR (95% CI) p\n",
      "\n",
      "Serum AST 1.01 (0.98–1.03) 0.63\n",
      "\n",
      "Serum ALT 1.00 (0.99–1.01) 0.98\n",
      "\n",
      "Serum lactate 0.42 (0.08–2.07) 0.29\n",
      "\n",
      "Chest radiograph performed 0.45 (0.22–0.93) 0.03\n",
      "\n",
      "Chest radiograph findings 0.38 (0.13–1.14) 0.08\n",
      "\n",
      "*Associations of baseline demographics and clinical findings of COVID-19 subjects with anosmia were determined using univariable (reporting ORs) and multivariable\n",
      "(reporting aORs) logistic regression models. Dependent variable = anosmia.\n",
      "ALT = alanine aminotransferase; aOR = adjusted odds ratio; AST = aspartate aminotransferase; BMI = body mass index; CI = confidence interval; COPD = chronic\n",
      "obstructive pulmonary disease; COVID-19 = coronavirus 2019; HIV = human immunodeficiency virus; OR = odds ratio.\n",
      "\n",
      "severity of olfactory dysfunction correlate with differences\n",
      "in self-reported loss.\n",
      "\n",
      "Assessment of smell may not only aid in the diagnosis of\n",
      "COVID-19 infection during pretest screening, but also help\n",
      "guide the posttest triaging of patients at all levels. Patients\n",
      "with influenza-like symptoms concerning for COVID-19\n",
      "infection but without anosmia should be more vigilant and\n",
      "present earlier for evaluation and management. Although\n",
      "in this particular study we did not ask subjects the timing\n",
      "of smell loss onset in relationship to their other symptoms,\n",
      "it has previously been shown that 33% to 60% of anosmic\n",
      "COVID-19 patients reported smell loss either before or at\n",
      "the same time of other symptoms.9,12,15 Of the self-reported\n",
      "anosmic/hyposmic inpatients, 12 of 20 (60%) noted on-\n",
      "set of smell loss prior to admission whereas 91% experi-\n",
      "enced taste loss before admission, which we suspect may\n",
      "be a profound anosmia impairing the odorant component\n",
      "of flavor.15 Furthermore, epidemiologic studies found that\n",
      "the average time from symptom onset to admission was 11\n",
      "days.18 These data, taken together, suggest that profound\n",
      "anosmia is a relatively early manifestation, whereas admis-\n",
      "sion tends to occur relatively late in the disease process. Al-\n",
      "though smell loss may not yet be manifested for all patients\n",
      "at the time of their evaluation by a healthcare professional,\n",
      "it still may be a useful early indicator in the majority of\n",
      "patients. If the findings reported here remain consistent in\n",
      "independent cohorts, anosmia/hyposmia could be consid-\n",
      "ered as a clinical marker inversely related to disease severity.\n",
      "As such, anosmia/hyposmia could be included in the clini-\n",
      "cal assessment of disease severity and potentially aid in the\n",
      "allocation of limited medical interventions. Just as Apgar\n",
      "scores are an effective means to rapidly assess and triage\n",
      "at-risk newborns,20 a future COVID-19 risk stratification\n",
      "model may have a potential to improve resource allocation\n",
      "and thereby save lives. Further research is needed to shed\n",
      "light on clinical findings, upon which a model based on dis-\n",
      "ease severity as shown in Figure 1 could be built. Although\n",
      "the presented hypothetical model is not intended to substi-\n",
      "tute for nuanced, patient-driven clinical decision making,\n",
      "it may in the future serve as a general model to organize\n",
      "decision making and risk stratification. Further study and\n",
      "validation of all risk factors will evolve as the pandemic\n",
      "\n",
      "FIGURE 1. Presentation of a hypothetical model suggesting that effective\n",
      "risk and response stratification of all levels of COVID-19 disease severity\n",
      "may assist in efficient allocation of limited resources. *Risk factors for severe\n",
      "and critical disease based on early reports on the COVID-19 pandemic.16-18\n",
      "\n",
      "COVID-19 = coronavirus 2019.\n",
      "\n",
      "progresses, but anosmia is emerging early as an important\n",
      "clinical component of both COVID-19 diagnosis and po-\n",
      "tentially outcome as well.\n",
      "\n",
      "Beyond the immediate practical applications of anosmia\n",
      "in addressing the pandemic, these findings potentially hint\n",
      "at some characteristics of the pathophysiology of the infec-\n",
      "tion. The site and dosage of the initial viral burden, along\n",
      "with the effectiveness of the host immune response are all\n",
      "potentially important variables in determining the spread\n",
      "of the virus within an individual and ultimately the clinical\n",
      "course of infection. A focused, small upper airway SARS-\n",
      "CoV-2 viral load may be associated with a less fulminant\n",
      "infection, decreasing the risk of overwhelming the host im-\n",
      "mune response and subsequently, decreasing the risk of res-\n",
      "piratory failure and hospitalization. This hypothesis, is in\n",
      "essence the concept underlying live vaccinations, where low\n",
      "dosage and distant site of inoculation generates an immune\n",
      "response without provoking a severe infection.21\n",
      "\n",
      "Similarly, anosmia may be a biomarker of the magnitude\n",
      "of a host’s innate immune response to SARS-CoV-2 infec-\n",
      "tion. Although the mechanism of olfactory loss remains\n",
      "unclear, radiographic imaging of a single case of isolated\n",
      "anosmia and COVID-19 infection shows bilateral olfactory\n",
      "\n",
      "International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020 829\n",
      "\n",
      "\n",
      "\n",
      "Yan et al.\n",
      "\n",
      "cleft obstruction consistent with local inflammation.22 This\n",
      "finding may be consistent with a greater local immune re-\n",
      "sponse in the infection of patients presenting with anosmia\n",
      "leading to an olfactory loss secondary to local infection and\n",
      "edema and perhaps a milder overall clinical course. Indeed,\n",
      "early, pre–peer review analyses of transcriptome data sug-\n",
      "gest that the candidate receptors mediating cellular entry\n",
      "of SARS-CoV-2, angiotensin converting enzyme 2 (ACE2)\n",
      "and transmembrane serine protease 2 (TMPRSS2), are ex-\n",
      "pressed on olfactory epithelial support cells and not on\n",
      "olfactory sensory neurons.23,24 Taken together, data show-\n",
      "ing that SARS-CoV2 infects olfactory epithelia and causes\n",
      "highly localized inflammation of the olfactory cleft suggest\n",
      "that COVID-19–related olfactory dysfunction may result in\n",
      "a conductive olfactory loss. Such a phenomenon would be\n",
      "consistent with relatively rapid recovery of olfactory func-\n",
      "tion with the resolution of viral infection in most patients,\n",
      "consistent with previously reported clinical findings.9 In ad-\n",
      "dition, these preliminary findings may be consistent with a\n",
      "greater local immune response in patients presenting with\n",
      "anosmia that may be indicative of a milder overall clinical\n",
      "course. The inverse association of anosmia and sputum pro-\n",
      "duction (OR 0.26) in the present study suggest that anos-\n",
      "mic COVID-19 are less likely to have a symptom associated\n",
      "with more severe lower airway inflammatory response. Al-\n",
      "though these are tantalizing hypotheses of the underlying\n",
      "pathophysiology currently only supported by piecemeal,\n",
      "circumstantial molecular and clinical findings, significant\n",
      "investigations into SARS-CoV-2 infection of airway mu-\n",
      "cosa and the host immune response are required to begin\n",
      "elucidating the underlying pathophysiology of the present\n",
      "study’s clinical observations.\n",
      "\n",
      "Additionally, further studies are warranted to validate\n",
      "our clinical findings. Limitations include the use of self-\n",
      "reported anosmia/hyposmia, particularly in those who re-\n",
      "ported anosmia after being informed of COVID-19 diagno-\n",
      "sis. This group is most susceptible to recall bias. Therefore,\n",
      "findings herein and elsewhere based on self-reported anos-\n",
      "mia after COVID-19 diagnosis should be validated in future\n",
      "studies with quantitative testing of olfaction. In other dis-\n",
      "ease processes there is discrepancy between self-reported\n",
      "anosmia and measured anosmia.25 Furthermore, the design\n",
      "of the questions posed to the subjects in this particular study\n",
      "did not specifically assess the severity of smell loss, but only\n",
      "if there was a loss of smell during their illness. Thus, in this\n",
      "analysis, we cannot draw a distinction between hyposmia\n",
      "\n",
      "and anosmia. However, our prior study did assess severity\n",
      "of smell loss and those who reported smell loss typically\n",
      "recalled complete functional anosmia.9 Our study has also\n",
      "achieved a higher response rate from ambulatory COVID-\n",
      "19 patients, some of whom were unable to be evaluated for\n",
      "olfactory function due to their clinical status. As a result,\n",
      "our data does not inform any potential relationship be-\n",
      "tween anosmia and critical illness requiring intensive care\n",
      "monitoring and intubation, or mortality. Notwithstanding\n",
      "these limitations, in the absence of objective olfactory test-\n",
      "ing, self-reported anosmia retains robust associations with\n",
      "specific COVID-19–related disease features.\n",
      "\n",
      "Our report is among the minority of reports focusing on\n",
      "mild to moderate COVID-19 in which we attempt to eluci-\n",
      "date clinical features to differentiate between patients with\n",
      "mild disease who could be managed at home and “mod-\n",
      "erately” sick patients who require admission and may be\n",
      "at risk of further clinical deterioration. Prospective studies\n",
      "are required to better determine the extent to which anos-\n",
      "mia informs overall disease trajectory. Most early data have\n",
      "focused on severely ill patients,16-18 but as the pandemic ap-\n",
      "proaches plateau and eventually passes its peak, the clinical\n",
      "characteristics of the moderately sick patient are important\n",
      "to identify and administer early intervention before a sub-\n",
      "set succumbs to critical, potentially fatal infection. Further\n",
      "research is required to validate the association between ol-\n",
      "factory function and hospitalization risk in patients with\n",
      "COVID-19, which may include prospective, longitudinal,\n",
      "and larger multi-institutional studies.\n",
      "\n",
      "Conclusion\n",
      "The current study has identified a strong inverse association\n",
      "between COVID-19–related anosmia and a critical branch\n",
      "point in management of COVID-19: the decision to com-\n",
      "mit to hospital admission. Patients admitted for COVID-19\n",
      "were 10 times less likely to report anosmia. These find-\n",
      "ings have important immediate practical applications to\n",
      "the lay public as well as healthcare workers and health-\n",
      "care systems looking to efficiently risk-stratify patients to\n",
      "efficiently provide appropriate medical and nonmedical in-\n",
      "terventions. The association between olfactory dysfunction\n",
      "and clinical outcomes also carries important implications\n",
      "for future investigations seeking to understand the abil-\n",
      "ity of SARS-CoV-2 virus to overwhelm the host immune\n",
      "response.\n",
      "\n",
      "References\n",
      "1. Phua J, Weng L, Ling L, et al. Intensive care man-\n",
      "\n",
      "agement of coronavirus disease 2019 (COVID-19):\n",
      "challenges and recommendations. Lancet Respir Med.\n",
      "2020;8:506-517.\n",
      "\n",
      "2. Wu Z, McGoogan JM. Characteristics of and\n",
      "important lessons from the coronavirus disease\n",
      "2019 (COVID-19) outbreak in China: summary\n",
      "of a report of 72 314 cases from the Chi-\n",
      "nese Center for Disease Control and Preven-\n",
      "tion. JAMA. (in press). Epub 24 February 2020.\n",
      "https://doi.org/10.1001/jama.2020.2648.\n",
      "\n",
      "3. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical char-\n",
      "acteristics of patients who died of coronavirus disease\n",
      "2019 in China. JAMA Netw Open. 2020;3:e205619.\n",
      "\n",
      "4. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-\n",
      "19 in critically ill patients in the Seattle region—\n",
      "case series. N Engl J Med. 2020;382:2012-2022.\n",
      "https://doi.org/10.1056/nejmoa2004500.\n",
      "\n",
      "5. Sutton D, Fuchs K, D’Alton M, Goffman D. Uni-\n",
      "versal screening for SARS-CoV-2 in women admit-\n",
      "ted for delivery. N Engl J Med. 2020;382:2163-2164.\n",
      "https://doi.org/10.1056/nejmc2009316.\n",
      "\n",
      "6. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen\n",
      "D. Clinical and epidemiological features of 36\n",
      "\n",
      "children with coronavirus disease 2019 (COVID-\n",
      "19) in Zhejiang, China: an observational co-\n",
      "hort study. Lancet Infect Dis. 2020;20:689-696.\n",
      "https://doi.org/10.1016/s1473-3099(20)30198-5.\n",
      "\n",
      "7. Guan W, Ni Z, Hu Y, et al. Clinical characteristics\n",
      "of coronavirus disease 2019 in China. N Engl J Med.\n",
      "2020;382:1708-1720.\n",
      "\n",
      "8. Xie J, Tong Z, Guan X, Du B, Qiu H, Slutsky AS.\n",
      "Critical care crisis and some recommendations dur-\n",
      "ing the COVID-19 epidemic in China. Intensive Care\n",
      "Med. 2020;46:837-840.\n",
      "\n",
      "9. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde\n",
      "AS. Association of chemosensory dysfunction and\n",
      "\n",
      "830 International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020\n",
      "\n",
      "https://doi.org/10.1001/jama.2020.2648\n",
      "https://doi.org/10.1056/nejmoa2004500\n",
      "https://doi.org/10.1056/nejmc2009316\n",
      "https://doi.org/10.1016/s1473-3099(20)30198-5\n",
      "\n",
      "\n",
      "Smell loss linked to milder form of COVID-19\n",
      "\n",
      "Covid-19 in patients presenting with influenza-\n",
      "like symptoms. Int Forum of Allergy Rhinol.\n",
      "(806-813). Epub 12 April 2020. https://doi.org/\n",
      "10.1002/alr.22579.\n",
      "\n",
      "10. Menni C, Valdes A, Freydin MB, et al. Real-\n",
      "time tracking of self-reported symptoms to\n",
      "predict potential COVID-19. Nat Med. 2020.\n",
      "https://doi.org/10.1038/s41591-020-0916-2.\n",
      "\n",
      "11. Moein ST, Hashemian SMR, Mansourafshar B,\n",
      "Khorram-Tousi A, Tabarsi P, Doty RL. Smell dys-\n",
      "function: a biomarker for COVID-19. Int Forum\n",
      "Allergy Rhinol. (in press). Epub 17 April 2020.\n",
      "https://doi.org/10.1002/alr.22587.\n",
      "\n",
      "12. Lechien JR, Chiesa-Estomba CM, De Siati DR,\n",
      "et al. Olfactory and gustatory dysfunctions\n",
      "as a clinical presentation of mild-to-moderate\n",
      "forms of the coronavirus disease (COVID-19): a\n",
      "multicenter European study. Eur Arch Otorhi-\n",
      "nolaryngol. (in press). Epub 06 April 2020.\n",
      "https://doi.org/10.1007/s00405-020-05965-1.\n",
      "\n",
      "13. Walker A, Hopkins C, Surda P. The use of\n",
      "google trends to investigate the loss of smell re-\n",
      "lated searches during COVID-19 outbreak. Int Fo-\n",
      "rum Allergy Rhinol. (in press). Epub 11 April 2020.\n",
      "https://doi.org/10.1002/alr.22580.\n",
      "\n",
      "14. Mao L, Jin H, Wang M, et al. Neurologic mani-\n",
      "festations of hospitalized patients with coronavirus\n",
      "disease 2019 in Wuhan, China. JAMA Neurol.\n",
      "(in press). Epub 10 April 2020. https://doi.org/10.\n",
      "1001/jamaneurol.2020.1127.\n",
      "\n",
      "15. Giacomelli A, Pezzati L, Conti F, et al. Self-reported ol-\n",
      "factory and taste disorders in SARS-CoV-2 patients: a\n",
      "cross-sectional study. Clin Infect Dis. (in press). Epub\n",
      "26 March 2020. https://doi.org/10.1093/cid/ciaa330.\n",
      "\n",
      "16. Yang J, Zheng Y, Gou X, et al. Prevalence of comor-\n",
      "bidities in the novel Wuhan coronavirus (COVID-19)\n",
      "infection: a systematic review and meta-analysis. Int J\n",
      "Infect Dis. 2020;94:91-95.\n",
      "\n",
      "17. Grasselli G, Zangrillo A, Zanella A, et al. Baseline\n",
      "characteristics and outcomes of 1591 patients infected\n",
      "with SARS-CoV-2 Admitted to ICUs of the Lombardy\n",
      "Region, Italy. JAMA. 2020;323:1574-1581.\n",
      "\n",
      "18. Zhou F, Yu T, Du R, et al. Clinical course and risk\n",
      "factors for mortality of adult inpatients with COVID-\n",
      "19 in Wuhan, China: a retrospective cohort study.\n",
      "Lancet. 2020;395:1054-1062.\n",
      "\n",
      "19. Wehling E, Nordin S, Espeseth T, Reinvang I, Lun-\n",
      "dervold AJ. Unawareness of olfactory dysfunction\n",
      "and its association with cognitive functioning in mid-\n",
      "dle aged and old adults. Arch Clin Neuropsychol.\n",
      "2011;26:260-269.\n",
      "\n",
      "20. Iliodromiti S, Mackay DF, Smith GCS, Pell JP, Nelson\n",
      "SM. Apgar score and the risk of cause-specific infant\n",
      "mortality: a population-based cohort study. Lancet.\n",
      "2014;384:1749-1755.\n",
      "\n",
      "21. Roestenberg M, Hoogerwerf M-A, Ferreira DM,\n",
      "Mordmüller B, Yazdanbakhsh M. Experimental in-\n",
      "fection of human volunteers. Lancet Infect Dis.\n",
      "2018;18:e312-e322.\n",
      "\n",
      "22. Eliezer M, Hautefort C, Hamel A-L, et al. Sud-\n",
      "den and complete olfactory loss function as a pos-\n",
      "sible symptom of COVID-19. JAMA Otolaryngol\n",
      "Head Neck Surg. (in press). Epub 08 April 2020.\n",
      "https://doi.org/10.1001/jamaoto.2020.0832.\n",
      "\n",
      "23. Brann D, Tsukahara T, Weinreb C, et al. Non-\n",
      "neural expression of SARS-CoV-2 entry genes\n",
      "in the olfactory epithelium suggests mecha-\n",
      "nisms underlying anosmia in COVID-19 pa-\n",
      "tients. bioRxiv. (in press). Epub 09 April 2020.\n",
      "https://doi.org/10.1101/2020.03.25.009084.\n",
      "\n",
      "24. Gupta K, Mohanty SK, Kalra S, et al. The molecular\n",
      "basis of loss of smell in 2019-NCoV infected individ-\n",
      "uals. Research Square Preprint. Epub 01 April 2020.\n",
      "https://doi.org/10.21203/rs.3.rs-19884/v1.\n",
      "\n",
      "25. Boesveldt S, Postma EM, Boak D, et al. Anosmia—a\n",
      "clinical review. Chem Senses. 2017;42:513-523.\n",
      "\n",
      "International Forum of Allergy & Rhinology, Vol. 10, No. 7, July 2020 831\n",
      "\n",
      "https://doi.org/10.1002/alr.22579\n",
      "https://doi.org/10.1002/alr.22579\n",
      "https://doi.org/10.1038/s41591-020-0916-2\n",
      "https://doi.org/10.1002/alr.22587\n",
      "https://doi.org/10.1007/s00405-020-05965-1\n",
      "https://doi.org/10.1002/alr.22580\n",
      "https://doi.org/10.1001/jamaneurol.2020.1127\n",
      "https://doi.org/10.1001/jamaneurol.2020.1127\n",
      "https://doi.org/10.1093/cid/ciaa330\n",
      "https://doi.org/10.1001/jamaoto.2020.0832\n",
      "https://doi.org/10.1101/2020.03.25.009084\n",
      "https://doi.org/10.21203/rs.3.rs-19884/v1\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(article_list[0][\"content\"])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Extract  -- Sections --"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_section(article_list, section_to_be_extracted, article_index):\n",
    "\n",
    "   #select certain article\n",
    "   article = article_list[article_index]\n",
    "   \n",
    "   section_req = {\"section\":section_to_be_extracted}\n",
    "\n",
    "   # add the section name to the existing json so we can send it via the request\n",
    "   article.update(section_req)\n",
    "   req = json.dumps(article, indent=1)\n",
    "\n",
    "   #print(article)\n",
    "\n",
    "   section_extraction_url = os.getenv('SECTION_EXTRACTION_FUNCTION')\n",
    "   #section_extraction_url = \"http://localhost:7071/api/section_identifier\"\n",
    "\n",
    "   res = requests.get(section_extraction_url, data=req)\n",
    "\n",
    "   print(res.status_code)\n",
    "\n",
    "   if section_to_be_extracted == \"All\":\n",
    "      section_to_be_extracted = \"Introduction\"\n",
    "\n",
    "   section_lowerletter = section_to_be_extracted.lower()\n",
    "   section = res.json()[section_lowerletter][0]\n",
    "   print(section)\n",
    "\n",
    "\n",
    "   #save file for further use without having to run the services again\n",
    "   #save_file('texts/article_' + str(article_index), section_lowerletter + '.txt', section)\n",
    "\n",
    "   return section\n",
    "   \n",
    "def save_file(dir_path, filename, file_content):\n",
    "   os.makedirs(dir_path, exist_ok=True)\n",
    "   with open(os.path.join(dir_path, filename), 'w', encoding=\"utf-8\") as f:\n",
    "      f.write(file_content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "200\n",
      "The current study has identified a strong inverse association\n",
      "between COVID-19–related anosmia and a critical branch\n",
      "point in management of COVID-19: the decision to com-\n",
      "mit to hospital admission. Patients admitted for COVID-19\n",
      "were 10 times less likely to report anosmia. These find-\n",
      "ings have important immediate practical applications to\n",
      "the lay public as well as healthcare workers and health-\n",
      "care systems looking to efficiently risk-stratify patients to\n",
      "efficiently provide appropriate medical and nonmedical in-\n",
      "terventions. The association between olfactory dysfunction\n",
      "and clinical outcomes also carries important implications\n",
      "for future investigations seeking to understand the abil-\n",
      "ity of SARS-CoV-2 virus to overwhelm the host immune\n",
      "response.\n",
      "\n",
      "\n",
      "\n",
      "~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\n",
      "\n",
      "\n",
      "200\n",
      "\n",
      "According to our results, the prevalence of gustatory and\n",
      "olfactory dysfunction in COVID-19 patients was almost\n",
      "\n",
      "57.33% and 59.69%, respectively. This dysfunction\n",
      "encompassed either complete or partial loss of these sen-\n",
      "sations or any noticeable alteration in them. This preva-\n",
      "\n",
      "lence may, in fact, be an underestimation of the true\n",
      "prevalence because most included studies did not use vali-\n",
      "dated tools/tests to detect OGD. The neurotropic nature of\n",
      "SARS-CoV-2 is explained by the high neuronal and glial\n",
      "\n",
      "cell expression of ACE-2 receptors, while direct damage to\n",
      "glossal and olfactory receptors plays a pathogenic role as\n",
      "well. Evaluating olfactory and gustatory functions both\n",
      "\n",
      "objectively and subjectively will be helpful in primary\n",
      "screening because PCR testing imposes significant con-\n",
      "straints on medical resources.\n",
      "\n",
      "\n",
      "\n",
      "~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\n",
      "\n",
      "\n",
      "200\n",
      "\n",
      "Although there have been few reports of definite change in \n",
      "smell and taste perception in patients with COVID-19, the \n",
      "findings of these studies raise the question whether SARS-\n",
      "CoV-2 may cause olfactory and gustatory dysfunctions [2, \n",
      "13, 21, 22]. The results of our study support recent reports \n",
      "that SARS-CoV-2 may infect oral and nasal tissues and \n",
      "cause olfactory and gustatory dysfunctions. These findings \n",
      "may aid future research on the diagnosis, prevention and \n",
      "treatment of COVID-19 consequences.\n",
      "\n",
      "\n",
      "\n",
      "~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\n",
      "\n",
      "\n",
      "200\n",
      "\n",
      "Since the disease is new and the virus is most likely asso-\n",
      "ciated with different mutations and clinical patterns, as of \n",
      "yet, there remain more questions than answers. This study \n",
      "is the first to identify both olfactory and gustatory dysfunc-\n",
      "tions as significant symptoms in the clinical presentation of \n",
      "the European COVID-19 infection. Based on our results, it \n",
      "seems that infected patients may just present olfactory and \n",
      "gustatory dysfunctions without other significant complaints. \n",
      "The sudden anosmia or ageusia need to be recognized by the \n",
      "international scientific community as important symptoms \n",
      "of the COVID-19 infection. Future epidemiological, clinical, \n",
      "and basic science studies must elucidate the mechanisms \n",
      "underlying the development of these symptoms in such a \n",
      "specific world population.\n",
      "\n",
      "\n",
      "\n",
      "~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\n",
      "\n",
      "\n",
      "200\n",
      "\n",
      "This study confirmed that olfactory dysfunction can be a chronic symptom even eight months\n",
      "\n",
      "after COVID-19. Interestingly, hypogeusia, a rare symptom during the acute infection, has\n",
      "\n",
      "been psychophysically confirmed in 32% of the study population. This must be seen as a fre-\n",
      "\n",
      "quent symptom of post-COVID-19 condition and might be partly due to a decreased central\n",
      "\n",
      "nervous amplification.\n",
      "\n",
      "\n",
      "\n",
      "~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "#VARIABLES \n",
    "# which section to extract\n",
    "# USE FIRST LETTER AS A CAPITAL LETTER\n",
    "# Workable: Introduction, Methods, Results, Discussion, Conclusion\n",
    "# Check section_identifier function for variations of the names (don't change them here)\n",
    "section_to_be_extracted = \"Conclusion\" \n",
    "\n",
    "# which article to extract from\n",
    "#article_index = 0\n",
    "#section = extract_section(article_list, section_to_be_extracted, article_index)\n",
    "\n",
    "conclusion_list = []\n",
    "\n",
    "# not neccessarily needed to create the conclusion list\n",
    "for i in range(document_count):\n",
    "   \n",
    "   conclusion_list.append(extract_section(article_list, section_to_be_extracted, i))\n",
    "   print(\"\\n\\n~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~\\n\\n\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Although there have been few reports of definite change in \n",
      "smell and taste perception in patients with COVID-19, the \n",
      "findings of these studies raise the question whether SARS-\n",
      "CoV-2 may cause olfactory and gustatory dysfunctions [2, \n",
      "13, 21, 22]. The results of our study support recent reports \n",
      "that SARS-CoV-2 may infect oral and nasal tissues and \n",
      "cause olfactory and gustatory dysfunctions. These findings \n",
      "may aid future research on the diagnosis, prevention and \n",
      "treatment of COVID-19 consequences.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(conclusion_list[2])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#DEBUGGING PURPOSES\n",
    "import re\n",
    "#text = \"sdfsfds\\n\\nConclusion\\n\\nRTDHDDGDE\\nGRTHNBTRDHNT\\n\\nResult and ethics\\n\\nskhfgksdfhsdfhku\\n\\ngfbfgfgfr\\n\\n.\\n\\nDiscussion\\n\\nJingleBells\"\n",
    "\n",
    "text = article[\"content\"]\n",
    "\n",
    "sec_name = \"Conclusion\"\n",
    "edge = \"References\"\n",
    "\n",
    "ed = edge.lower()\n",
    "\n",
    "regex_terms = r'\\n' + sec_name+ r'\\n(.|\\n)+\\n' + edge + r'\\n'\n",
    "\n",
    "x = re.search(regex_terms, text)[0]\n",
    "\n",
    "\n",
    "y = x.replace(\"\\\\n\\\\nConclusion\\\\n\\\\n\", \"\")\n",
    "z = y.replace(\"\\\\n\\\\nDiscussion\\\\n\\\\n\", \"\")\n",
    "w = z.replace(\"\\\\n\\\\nResult\\\\n\\\\n\", \"\")\n",
    "print(x)\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3.9.2 64-bit",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.2"
  },
  "orig_nbformat": 4,
  "vscode": {
   "interpreter": {
    "hash": "81794d4967e6c3204c66dcd87b604927b115b27c00565d3d43f05ba2f3a2cb0d"
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
